BEIJING, Nov. 2, 2015 (GLOBE NEWSWIRE) -- BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the appointment of Dr. RuiRong Yuan as Chief Medical Officer and President of Global Clinical Development. Dr. Yuan brings extensive international clinical experience having worked across the United States, Europe and Asia. Dr. Yuan will be responsible for driving the development of BeiGene's portfolio of drug candidates through to regulatory approval, as well as contributing to design and providing overall medical and safety oversight for BeiGene's oncology clinical trials.
John V. Oyler, CEO of BeiGene, said, "We are very excited to have RuiRong join us. Her experience in oncology, spanning from academic research to drug development, will be a welcome addition to the team. We very much look forward to her input in the continued growth and development of our pipeline assets and the company as a whole."
Dr. Yuan joins BeiGene from Eisai Global Oncology where she served as Chief Medical Officer and Head of Americas Oncology Medical Research & Strategy. Previously she spent time as Head of Oncology and other therapeutic areas at Daiichi Sankyo where she was responsible for their early and late stage clinical programs in the United States. Prior to this Dr. Yuan was a Senior Global R&D Clinical Leader at Novartis Oncology where she led global teams conducting registrational studies for Afinitor and supported its successful regulatory approval in patients with renal cell carcinoma. Dr. Yuan began her career as a medical oncologist and completed post-doctoral fellowships in the same and associated fields.
Dr. Yuan is a founding member of the Chinese American Hematologist and Oncologist Network (CAHON), where she has also previously served as both President and Chairman of the Board of Directors. She earned her medical doctor degrees from Shandong Medical University, China, and The University of Bern, Switzerland, and her post-doctoral fellowship in immunology from the Albert Einstein College of Medicine (AECOM), United States. She was U.S. board-certified in both internal medicine and medical oncology after her clinical oncology and hematology fellowship at Cancer Hospital of Peking Union Medical College, China, and Memorial Sloan Kettering Cancer Center, United States.
BeiGene is a global, clinical-stage, research-based company focused on targeted and immuno-oncology therapeutics. With a team of 175+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions that will have both a meaningful and lasting impact on cancer patients. For more information, please visit our website at www.beigene.com.
CONTACT: Media/Investor Contact: Xin Huang US: +1 917-617-4653 China: +86 185-1406-3050 firstname.lastname@example.org